References
- Siemianowicz K., Francuz T., Gminski J., Telega A., Syzdol M. Endothelium dysfunction markers in patients with diabetic retinopathy. Int J Mol Med 2005; 15: 459–62
- Boulbou M. S., Koukoulis G. N., Petinaki E. A., Germenis A., Gourgoulianis K. I. Soluble adhesion molecules are not involved in the development of retinopathy in type 2 diabetic patients. Acta Diabetol 2004; 41: 118–22
- Hogg N., Landis R. C. Adhesion molecules in cell interactions. Curr Opin Immunol 1993; 5: 383–90
- Mackay C. R., Imhof B. A. Cell adhesion in the immune system. Immunol Today 1993; 14: 99–102
- Ryysy L., Yki‐Jarvinen H. Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE‐selectin concentrations in type 2 diabetes. Diabetes Care 2001; 24: 549–54
- Hughes J. M., Brink A., Witmer A. N., Hanraads‐de Riemer M., Klaassen I., Schlingemann R. O. Vascular leucocyte adhesion molecules unaltered in the human retina in diabetes. Br J Ophthalmol 2004; 88: 566–72
- Knudsen S. T., Foss C. H., Poulsen P. L., Bek T., Ledet T., Mogensen C. E., et al. E‐selectin‐inducing activity in plasma from type 2 diabetic patients with maculopathy. Am J Physiol Endocrinol Metab 2003; 284: E1–6
- Elhadd T. A., Kennedy G., Robb R., McLaren M., Jung R. T., Belch J. J. F. Elevated soluble cell adhesion molecules E‐selectin and intercellular cell adhesion molecule‐1 in type 2 diabetic patients with and without asymptomatic peripheral arterial disease. Int Angiol 2004; 23: 128–33
- Matthews D. R., Hosken J. P., Rudenski A. S., Naylor B. A., Treacher D. F., Turner R. C. Homeostasis model assessment: insulin resistance and beta‐cell function, from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9
- Koch A. E., Halloran M. M., Haskell C. J., Shah M. R., Polverini P. J. Angiogenesis mediated by soluble forms E‐selectin and vascular cell adhesion molecule‐1. Nature 1995; 376: 517–9
- Caballero A. E., Arora S., Saouaf R., Lim S. C., Smakowski P., Park J. Y., et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48: 1856–62
- Meigs J. B., Hu F. B., Rifai N., Manson J. A. E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291: 1978–86
- Albertini J. P., Valensi P., Lormeau B., Aurousseau M. H., Ferriere F., Attali J. R., et al. Elevated concentrations of soluble E‐selectin and vascular cell adhesion molecule‐1 in NIDDM: effect of intensive insulin treatment. Diabetes Care 1998; 21: 1008–13
- Kado S., Nagata N. Circulating intercellular adhesion molecule‐1, vascular cell adhesion molecule‐1, and E‐selectin in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 1999; 46: 143–8
- Gearing A. J. H., Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506–12
- Fasching P., Veitl M., Rohac M., Streli C., Schneider B., Waldhausl W., et al. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin‐dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4313–7
- Matsumoto K., Sera Y., Ueki Y., Inukai G., Niiro E., Miyake S. Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med 2002; 19: 822–6
- Cominacini L., Fratta A., Garbin U., Davoli A., De Santis A., Campagnola M., et al. Elevated levels of soluble E‐selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 1995; 38: 1122–4
- Baumgartner‐Prazer S. M., Wagner L., Petterman M., Gesse A., Waldhaus W. Modulation by high glucose adhesion molecule expression in cultured endothelial cells. Diabetologia 1995; 38: 1367–70
- Limb G. A., Hickman‐Casey J., Hollifield R. D., Chignell A. H. Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1999; 40: 2453–7
- Hernandez C., Burgos R., Canton A., Garcia‐Arumi J., Segura R. M., Rimo R. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case‐control study. Diabetes Care 2001; 24: 516–21